Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 4, 2025 8:30 AM EDTRADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days
Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen
Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development
Cash and investments of approximately $447... More
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
August 4, 2025 8:00 AM EDTDosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency
Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment
Rapid and sustained response, with over 54% of patients achieving 50% response in the first week
Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) --... More
